Universität Leipzig

Permanent URI for this communityhttp://opara.zih.tu-dresden.de/handle/123456789/28

Research data repository of Leipzig University.

Browse

Browsing Universität Leipzig by Subject "2::22"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • ItemOpen Access
    Discrimination of human and animal bloodstains using hyperspectral imaging
    (Universität Leipzig, 2024-04-26) Babian, Carsten; Cooney, Gary Sean; Chalopin, Claire; Köhler, Hannes
    To address the question of blood origin, the novel application of visible-near infrared hyperspectral imaging (HSI) is used for the detection and discrimination of human and animal bloodstains. The HSI system used is a portable, non-contact, non-destructive method for the determination of blood origin. A support vector machine (SVM) binary classifier was trained for the discrimination of bloodstains of human (n = 20) and five animal species: pig (n = 20), mouse (n = 16), rat (n = 5), rabbit (n = 5), and cow (n = 20).
  • ItemOpen Access
    Supplemental material for the publication "Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity"
    (Universität Leipzig, 2025-12-02) Prengemann, Lea; Stein, Robert; Gausche, Ruth; Beger, Christoph; Vogel, Mandy; Wenzel, Eric; Stoltze, Anette; Kiess, Wieland; Pfäffle, Roland; Körner, Antje
    Background and Objectives: Being born small for gestational age (SGA) and growth hormone (GH) treatment are linked to disturbed glucose-insulin metabolism. We investigated how GH treatment affects glucose-insulin metabolism in children born SGA compared to children with isolated growth-hormone deficiency (iGHD), obesity and lean controls. Methods: We analyzed glucose-insulin metabolism indices derived from OGTTs (Matsuda index, AUC insulin) and fasting parameters (fasting glucose, HOMA-IR) in 134 SGA patients without catch-up growth (CUG) receiving GH therapy (SGA-GHT), 27 untreated SGA patients with catch-up growth (SGA-CUG), 308 iGHD patients under GH treatment, 427 children with obesity and 356 lean controls. We adjusted for sex, age and BMI through matching and multivariable regression. Results: Treatment-naïve SGA-GHT patients were more insulin-resistant than iGHD patients (higher insulin AUC (p=0.002) and HOMA-IR (p<0.001), lower Matsuda index (p<0.001)) with levels approaching those of the obesity cohort. Under GH therapy, HbA1c was higher in SGA-GHT and iGHD patients (5.26%±0.35 vs. 5.25%±0.25) than in lean controls (5.09%±0.27). Insulin resistance in SGA-GHT patients approached levels seen in obesity. The prevalence of prediabetes was highest in SGA-GHT children (11.11%) compared to those with iGHD (1.59%) or obesity (3.13%). After stopping GH therapy, SGA-GHT patients retained elevated markers of prediabetes (4.65%) and insulin resistance compared to controls and iGHD patients, similar to children with obesity (6.38%). No overt type 2 diabetes was observed. Conclusion: SGA patients have an impaired glucose-insulin metabolism similar to that of children with obesity, which worsens under GH therapy. Close metabolic monitoring of GH-treated SGA patients is recommended.